CD99-L2 Antibody [Alexa Fluor® 647]

• Applications: WB, Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 647

CD99-L2 Antibody [Alexa Fluor® 647] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse CD99-L2
  Val20-Ala141
  Accession # NP_612182
• Specificity: Detects mouse CD99-L2 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human CD99‑L2 and recombinant mouse CD99 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

CD99 antigen-like 2 (CD99-L2) is a 45 kDa type I transmembrane glycoprotein in the CD99 family of molecules (1-3). Mouse CD99-L2 cDNA encodes a 214 amino acid (aa) precursor with a 23 aa predicted signal sequence, a 116 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 54 aa cytoplasmic region (4). The ECD contains no N-linked glycosylation sites, but O-linked glycosylation is likely (1, 2). A long isoform with a 23 aa insert after aa 43 within the ECD is expressed in human, and probably in mouse (2, 5). Both long and short isoforms may have minor variants missing portions of the N-terminus of the mature protein (6). The ECD of mouse CD99-L2 short isoform shares 85%, 72% and 66% aa identity with rat, human, and bovine CD99-L2, respectively (3, 5). The mouse CD99 and CD99-L2 ECDs share only 31% aa identity, but both contain three conserved acidic motifs and are thought to originate from the same ancestral gene (1, 2). The nearly ubiquitous expression of CD99-L2 is similar to that of CD99. Mouse CD99-L2 shows highest in situ hybridization signals in neurons, cortical thymocytes, ganglia, ovarian granulosa cells, testis, and kidney, and detectable protein levels in lung, thymocytes, mouse leukocytes and vascular endothelial cells (2, 7). CD99‑L2 expression on endothelial cells is reported to mediate cell aggregation and neutrophil or monocyte extravasation to inflamed tissue in vivo, while CD99 mediates lymphocyte extravasation as well (3, 7).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.